Researchers reported the findings of the phase III trial evaluating the Omicron BA.1–adapted mono and bivalent BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in 55-year-old adults. These individuals had already received three 30μg doses of the BNT162b2 …